Neurocrine Biosciences Inc vs Valero Energy Corporation — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Valero Energy Corporation trades at $442.5 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 8.9× Neurocrine Biosciences Inc's market cap, and Valero Energy Corporation pays a 1.08% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Valero Energy Corporation for 56 Days on average.
| NBIX | VLO | |
|---|---|---|
Market Cap | $14.36B | $127.78B |
Volume | 1,237,180 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $185.50 | $443.80 |
52-Week Low | $123.10 | $156.39 |
Typical Hold Time | 23 Days | 56 Days |
Enterprise Value | $14.37B | $131.26B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Valero Energy (VLO) trades at $424.10, up 1.16% today, near its 52-week high. The stock exhibits bullish technical signals with strong moving average alignment and has beaten earnings estimates for three consecutive quarters. Revenue declined to $122.69 billion in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a $408.10 price target, and recent news highlights institutional buying and refining margin strength.
Outlook remains positive driven by earnings beats and supportive refining margins, but risks include potential diesel export policy changes and volatile energy markets. The stock's high RSI suggests near-term overbought conditions, yet fundamental improvements and strong cash flow projections for 2026 provide a solid foundation for continued investor interest.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →